Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the <scp>ALLEGRO</scp> phase 2b/3 randomized, double‐blind, placebo‐controlled trial

Abstract

Ritlecitinib treatment demonstrated clinician-reported efficacy, patient-reported improvement, and an acceptable safety profile through Week 48 in adolescents with AA with ≥50% scalp hair loss.